A key opinion leader examines the historical context of Demodex blepharitis treatment, discussing the efficacy and limitations of previous therapies, and emphasizes a recently FDA-approved therapy that directly targets Demodex mites, leading to improved efficacy compared to treatments that only address symptoms.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More